A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

Phase 4

Completed

• Conditions: Hyperparathyroidism; Parathyroid Neoplasms

• Registration Number: NCT00037518
• Lead Sponsor: Amgen

Brief Summary

This study will assess an investigational medication for patients with severe primary hyperparathyroidism or parathyroid cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2001-04
• Study First Submitted: 2002-05-17
• Study First Submitted QC: 2002-05-17
• Study First Posted: 2002-05-20
• Status Verified: 2013-05
• Last Update Submitted: 2013-05-06
• Last Update Posted: 2013-05-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Changes in serum calcium and PTH

Secondary Outcome Measures

Name	Time	Method
Safety and tolerability of cinacalcet